Inflammatory injury is emerging as a central driver of idiopathic achalasia
Idiopathic achalasia remains one of the most enigmatic esophageal motility disorders in clinical practice. The defining lesion is not simply impaired swallowing mechanics, but the selective loss of enteric neurons that normally coordinate relaxation of the lower esophageal sphincter and peristalsis across the esophageal body. When those inhibitory myenteric neurons disappear, the physiology of swallowing collapses into the familiar syndrome of dysphagia, regurgitation, chest pain, and progressive weight loss.
The disease has been recognized for more than three centuries, yet its cause is still unresolved. This review frames achalasia less as a purely mechanical motility disorder and more as an inflammatory disease in which an initiating insult appears to set off a destructive immune cascade. Viral infection has long occupied the center of that discussion, but the authors broaden the lens to include genetic susceptibility, autoimmunity, psychological factors, the gut microbiota, and the gut-brain axis. The result is a model in which achalasia develops after injury, then persists because inflammation keeps targeting the neurons required for esophageal relaxation.
A single sentence captures the biology: once inhibitory neurons are lost, normal swallowing cannot be restored by symptom control alone.
Viral injury and immune activation may start the cascade
The review places early esophageal injury at the front of the pathogenic sequence. Viral infection remains the most frequently proposed trigger, not because a single pathogen has been definitively proven, but because the pattern fits a post-infectious inflammatory disorder. A transient infectious event could injure the esophageal wall, recruit immune cells, and expose neuronal antigens that are usually hidden from immune surveillance. In a genetically susceptible host, that initial insult may be enough to initiate a self-sustaining inflammatory response.
This model is attractive because it explains why the disease is uncommon despite the ubiquity of viral exposure. Most people clear an infection without chronic sequelae. In achalasia, however, the same exposure may lead to a prolonged immune reaction that targets the myenteric plexus. Over time, chronic inflammation would preferentially damage the inhibitory neurons that mediate lower esophageal sphincter relaxation, leaving behind the functional obstruction that defines the disorder.
The review does not reduce achalasia to infection alone. Instead, it treats infection as a trigger that gains clinical importance only when layered onto host susceptibility and maladaptive immune signaling.
Genetic susceptibility shapes who converts inflammation into disease
Genetic factors occupy a large part of the proposed explanation. The review emphasizes that infection and immune activation do not occur in a vacuum; they unfold in hosts with differing vulnerability to neuronal injury. Genetic predisposition may influence how the immune system responds to an infectious insult, how resilient the enteric nervous system is under inflammatory stress, and how readily tolerance breaks down after tissue damage.
This framework helps resolve a long-standing mismatch in achalasia research: the presence of proposed environmental triggers does not match the rarity of the disease. A common exposure should not produce a rare outcome unless the host response matters. Genetic susceptibility provides that missing filter. It also gives mechanistic coherence to the idea that achalasia is not simply the aftermath of one insult, but the endpoint of an interaction between inherited biology and acquired injury.
Autoimmunity explains the persistence of neuronal loss
Once the inflammatory process begins, autoimmunity becomes a plausible mechanism for progression. The review treats immune-mediated destruction of inhibitory myenteric neurons as the final common pathway. In practical terms, this means that even if the initial trigger is transient, the immune system may continue to attack neuronal tissue after the inciting event has passed.
That pattern matters clinically because it recasts achalasia as a disease of ongoing tissue injury rather than a static defect. Dysphagia develops when sphincter relaxation fails, but the deeper problem is neuronal depletion. If the inflammatory process continues unchecked, symptoms can worsen as neuronal reserve declines further. The esophagus then loses both coordinated peristalsis and the capacity for effective outlet relaxation, producing the classic manometric and clinical phenotype.
The review also places achalasia among disorders in which immune dysregulation and tissue-specific injury intersect. The implication is straightforward: therapies aimed only at symptom relief address the consequence, not the biological engine.
Psychological factors, microbiota, and the gut-brain axis extend the model
The most expansive part of the review is its proposal that psychological factors, gut microbiota, and the gut-brain axis may participate in achalasia pathogenesis. This is a more speculative layer of the model, but it is biologically plausible. Stress-related neuroimmune signaling can alter inflammatory tone, and the digestive tract is densely connected to central and enteric neural pathways. If those pathways are perturbed, esophageal function may be influenced not only by local inflammation but also by broader neuroimmune regulation.
Gut microbiota also deserve attention because microbial communities shape immune activity throughout the gastrointestinal tract. A disturbed microbiome could influence mucosal immunity, barrier function, and inflammatory signaling in ways that amplify or perpetuate neuronal injury. The review does not claim these factors are established causes of achalasia; instead, it argues that they deserve consideration because they may help explain heterogeneity in disease onset, severity, and progression.
The gut-brain axis provides a conceptual bridge between local esophageal pathology and systemic regulation. In a disease defined by failure of coordinated neuromuscular control, that bridge is particularly relevant.
A broader etiologic model may change how achalasia is studied
The practical value of this review lies in how it reorganizes the field. Rather than treating idiopathic achalasia as a mystery of esophageal mechanics alone, it positions the disorder as the end product of interacting immune, genetic, infectious, and neurobiological forces. That shift matters because it changes the questions researchers ask. Future studies will need to look beyond isolated infection markers or single genetic associations and instead examine how these elements converge in the same patient.
This also raises a bedside implication for clinical thinking. Patients present with the symptom complex of dysphagia and regurgitation, but the pathogenesis may have begun long before swallowing became difficult. By the time the lower esophageal sphincter fails to relax, the inflammatory injury may already have destroyed the neurons that could have preserved function. Treatment can relieve obstruction, but it cannot yet reverse the upstream biology described here.
A mechanistic framework is not the same as a cure, and the review is careful about that boundary. The central unanswered problem remains identifying which trigger starts the cascade, which host factors permit it to persist, and which pathways are most worth targeting before neuronal loss becomes irreversible.